Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567141 | 0.88 | NPC1 (0.58) | ALDH1A1HRH3NPC1RAB9A | |
| SCHEMBL606957 | 0.87 | CARM1 (0.50) | CARM1PRMT6ALDH1A1DRD4TMEM97 | |
| SCHEMBL605047 | 0.87 | SIGMAR1 (0.44) | CARM1PRMT6DRD4TMEM97SIGMAR1 | |
| SCHEMBL613535 | 0.86 | CARM1 (0.49) | CARM1PRMT6ALDH1A1DRD4TMEM97 | |
| SCHEMBL607258 | 0.86 | SIGMAR1 (0.44) | CARM1PRMT6DRD4TMEM97SIGMAR1 | |
| SCHEMBL605534 | 0.86 | CARM1 (0.49) | CARM1PRMT6DRD4TMEM97SIGMAR1 | |
| SCHEMBL605782 | 0.86 | SIGMAR1 (0.44) | CARM1PRMT6ALDH1A1DRD4TMEM97 | |
| SCHEMBL605692 | 0.86 | SIGMAR1 (0.44) | CARM1PRMT6ALDH1A1DRD4TMEM97 | |
| SCHEMBL606084 | 0.84 | ACHE (0.51) | HTR2BDRD4TMEM97SIGMAR1DRD3 | |
| SCHEMBL603712 | 0.83 | SIGMAR1 (0.42) | CARM1PRMT6DRD4TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| EP-1651634-A1 | IMIDAZOL DERIVATIVES OF PIPERIDINE AS HISTAMINE ANTAGONISTS | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014579-A1 | IMIDAZOL DERIVATIVES OF PIPERDINE AS HISTAMINE ANTAGONISTS | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | claimed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | HRH2, HRH1, HRH4 | CARM1 400/4885PRMT6 644/4885HTR2B 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.